Page 40 - Program Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

July 8, 5 p.m., Parks & Recreation Committee July 13, 7 p.m. Planning Commission July 14, 3 p.m. Cemetery Commission Aug. 2, 7 p.m. City Council Cass County Board of Commissioners Meets 9 a.m. Tuesday, July 6 Commissioners Board Room 1. 9 a.m. Call to Order b. Pledge of Allegiance. c. Approval of agenda for discussion. (Any requests to be heard not on the proposed agenda are considered for inclusion at this time.) 2. 9:05 a.m. Josh Stevenson - County Administrator a. Consent Agenda c. Cass County American Rescue Plan Act Grant Funding d. Establish Public Hearing for Fee Schedule Update e...

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 News provided by Share this article Share this article SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. "We are encouraged by our continued progress in first quarter of 2021, building on the accomplishm...

Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter ended March 31, 2021. "We are excited to advance IDE397, a potential best-in-class MAT2A inhibitor, in the Phase 1 dose escalation for evaluation in patients with MTAP deletion tumors, including in non-small cell lung cancer (NSCLC).  We are also...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ProQR Announces First Quarter 2021 Operating and Financial Results ProQR Therapeutics N.V.May 6, 2021 GMT Phase 2/3 pivotal  Illuminate  trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end Exclusive worldwide license and discovery c...